ACSL3

Across TCGA pan-cancer cohorts, ACSL3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACSL3 data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACSL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACSL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where ACSL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.678	0.931	<.001	36	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.438	.004	28	view →
HNSC	OS	Median	III,IV	0.344	1.000	.009	24	view →
GBM	OS	Median	All	0.974	0.738	<.001	14	view →
PDAC	DFS	Quartile	All	0.688	0.839	.006	12	view →
LSCC	OS	Tertile	II,III,IV	0.570	0.938	.006	11	view →
CCRCC	OS	Median	All	0.668	1.000	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACSL3–LUAD (OS)

Open the LUAD breakdown →